

OXFORD SPECIALIST HANDBOOKS

HEART FAILURE

FROM ADVANCED DISEASE TO BEREAVEMENT

Miriam Johnson

Karen Hogg

James Beattie

Series Editor: Max Watson



END OF LIFE CARE

Heart Failure

From advanced disease to bereavement

Miriam Johnson

Reader in Palliative Medicine
Hull York Medical School (HYMS)
Honorary Consultant in Palliative Medicine to
St Catherine's Hospice

Karen Hogg

Consultant Cardiologist
Glasgow Royal Infirmary and
Golden Jubilee National Hospital

James Beattie

Consultant Cardiologist
Heart of England NHS Foundation Trust Birmingham and
National Clinical Lead NHS Improvement—Heart

Series Editor

Max Watson

Consultant
Northern Ireland Hospice, Belfast
Honorary Consultant
Princess Alice Hospice, Esher
Visiting Professor
University of Ulster, Belfast

OXFORD
UNIVERSITY PRESS

OXFORD

UNIVERSITY PRESS

Great Clarendon Street, Oxford OX2 6DP
United Kingdom

Oxford University Press is a department of the University of Oxford.
It furthers the University's objective of excellence in research, scholarship,
and education by publishing worldwide. Oxford is a registered trade mark of
Oxford University Press in the UK and in certain other countries

© Oxford University Press 2012

The moral rights of the authors have been asserted

First Edition published in 2012

Impression: 1

All rights reserved. No part of this publication may be reproduced, stored in
a retrieval system, or transmitted, in any form or by any means, without the
prior permission in writing of Oxford University Press, or as expressly permitted
by law, by licence or under terms agreed with the appropriate reprographics
rights organization. Enquiries concerning reproduction outside the scope of the
above should be sent to the Rights Department, Oxford University Press, at the
address above

You must not circulate this work in any other form
and you must impose this same condition on any acquirer

British Library Cataloguing in Publication Data

Data available

Library of Congress Cataloging in Publication Data

Library of Congress Control Number: 2011944044

ISBN 978-0-19-929930-0

Printed in Great Britain

on acid-free paper by

Ashford Colour Press Ltd, Gosport, Hampshire

Oxford University Press makes no representation, express or implied, that the
drug dosages in this book are correct. Readers must therefore always check
the product information and clinical procedures with the most up-to-date
published product information and data sheets provided by the manufacturers
and the most recent codes of conduct and safety regulations. The authors and
the publishers do not accept responsibility or legal liability for any errors in the
text or for the misuse or misapplication of material in this work. Except where
otherwise stated, drug dosages and recommendations are for the non-pregnant
adult who is not breast-feeding

Links to third party websites are provided by Oxford in good faith and
for information only. Oxford disclaims any responsibility for the materials
contained in any third party website referenced in this work.

Oxford Specialist Handbooks published and forthcoming

General Oxford Specialist Handbooks

A Resuscitation Room Guide
Addiction Medicine
Perioperative Medicine,
Second Edition
Post-Operative Complications,
Second edition

Oxford Specialist Handbooks in Anaesthesia

Cardiac Anaesthesia
General Thoracic Anaesthesia
Neuroanaesthesia
Obstetric Anaesthesia
Paediatric Anaesthesia
Regional Anaesthesia, Stimulation
and Ultrasound Techniques

Oxford Specialist Handbooks in Cardiology

Adult Congenital Heart Disease
Cardiac Catheterization
and Coronary Intervention
Echocardiography
Fetal Cardiology
Heart Failure
Hypertension
Nuclear Cardiology
Pacemakers and ICDs

Oxford Specialist Handbooks in Critical Care

Advanced Respiratory Critical Care

Oxford Specialist Handbooks in End of Life Care

Cardiology
Dementia
Nephrology
Respiratory Disease
The Intensive Care Unit

Oxford Specialist Handbooks in Neurology

Epilepsy
Parkinson's Disease and Other
Movement Disorders
Stroke Medicine

Oxford Specialist Handbooks in Paediatrics

Paediatric Endocrinology and Diabetes
Paediatric Dermatology
Paediatric Gastroenterology,
Hepatology, and Nutrition
Paediatric Haematology and
Oncology
Paediatric Nephrology
Paediatric Neurology
Paediatric Radiology
Paediatric Respiratory Medicine

Oxford Specialist Handbooks in Psychiatry

Child and Adolescent Psychiatry
Old Age Psychiatry

Oxford Specialist Handbooks in Radiology

Interventional Radiology
Musculoskeletal Imaging

Oxford Specialist Handbooks in Surgery

Cardiothoracic Surgery
Hand Surgery
Hepato-pancreatobiliary Surgery
Oral Maxillo Facial Surgery
Neurosurgery
Operative Surgery, Second Edition
Otolaryngology and Head and Neck
Surgery
Plastic and Reconstructive Surgery
Surgical Oncology
Urological Surgery
Vascular Surgery

OXFORD MEDICAL PUBLICATIONS

Heart Failure

Contributors

Dr Miriam Johnson

Reader in Palliative Medicine
Hull York Medical School (HYMS)
Honorary Consultant in Palliative
Medicine to St Catherine's
Hospice

Dr Karen Hogg

Consultant Cardiologist
Glasgow Royal Infirmary and
Golden Jubilee National Hospital

Dr James Beattie

Consultant Cardiologist
Heart of England NHS Foundation
Trust Birmingham and
National Clinical Lead NHS
Improvement—Heart

Series Editor

Dr Max Watson

Consultant
Northern Ireland Hospice, Belfast
Honorary Consultant
Princess Alice Hospice, Esher
Visiting Professor
University of Ulster, Belfast

Additional contributions by:

Dr Shona Jenkins

SpR Cardiology
Glasgow Royal Infirmary

Dr Suzanne Kite MA FRCP

Consultant in Palliative Medicine
The Leeds Teaching Hospitals
NHS Trust

Mrs Annie MacCallum

Professional Lead for Specialist
Nursing Services
NHS Gloucestershire Care
Services

Acknowledgement

The chapters on Diagnosing end-stage heart disease (Chapter 5), Management of pain (Chapter 9), and Spiritual and religious care (Chapter 14) include adapted text from *End of Life Care in Nephrology: From Advanced Disease to Bereavement* by Edwina Brown, E Joanna Chambers and Celia Eggeling, Oxford University Press, 2007. With permission of Oxford University Press.

Symbols and abbreviations



	cross-reference in this book
AAs	aldosterone antagonists
ACE	angiotensin-converting enzyme
ACP	advance care planning
ADL	activities of daily living
ADRT	advance decision to refuse treatment
A&E	Accident and Emergency [hospital department]
AF	atrial fibrillation
ARBs	angiotensin II receptor antagonists
AV	atrioventricular [node]
B3G	buprenorphine-3-glucuronide
bd	twice a day
BHF	British Heart Foundation
BiVAD	biventricular assist device
BMA	British Medical Association
BNP	brain natriuretic peptide
BP	blood pressure
CABG	coronary artery bypass graft
CNS	central nervous system
COPD	chronic obstructive pulmonary disease
CPR	cardiopulmonary resuscitation
CrCL	creatinine clearance
CRT	cardiac resynchronization therapy [device]
CRTD	cardiac resynchronization therapy [device] with defibrillator
CRTP	CRT [with] pacemaker
DCM	dilated cardiomyopathy
DIG	Digitalis Investigation Group
DNACPR	do not attempt cardiopulmonary resuscitation
DVT	deep vein thrombosis
ECG	electrocardiogram
ESAS	Edmonton Symptom Assessment Scale
FPA	financial power of attorney
GMC	General Medical Council [UK]
GP	general practitioner
GSF	Gold Standards Framework

H3G	hydromorphone-3-glucuronide
HF	heart failure
HFNS	heart failure nurse specialist
HFSS	Heart Failure Survival Score
H-ISDN	hydralazine and isosorbide dinitrate
HIV	human immunodeficiency virus
hr	hour(s)
HRUK	Heart Rhythm UK
ICD	implantable cardioverter defibrillator
IABP	intra-aortic balloon pump
IV	intravenous
KCCQ	Kansas City Cardiomyopathy Questionnaire
KPS	Karnofsky Performance Status/Score
LCP	Liverpool Care Pathway [for the Dying]
LMWH	low molecular weight heparin
LPA	lasting power of attorney
LV	left ventricle
LVAD	left ventricular assist device
LVEF	left ventricular ejection fraction
M3G	morphine-3-glucuronide
M6G	morphine-6-glucuronide
mcg	microgram
mg	milligram
MI	myocardial infarction
MR	mitral regurgitation
MV	mitral valve
NaSSA	noradrenergic and specific serotonergic antidepressant
NICE	National Institute for Health and Clinical Excellence
NMDA	<i>N-methyl-D-aspartate</i>
NNT	number needed to treat
nocte	at night
NorB	norbuprenorphine
NRS	numerical rating scale
NSAID	non-steroidal anti-inflammatory drug
NYHA	New York Heart Association
od	once a day
OOH	out of hours
PCI	percutaneous coronary intervention
POA	power of attorney
PPA	property power of attorney

PPS	post-phlebitic syndrome
prn	as needed
qds	four times a day
RAAS	renin–angiotensin–aldosterone system
SARI	serotonin antagonist and re-uptake inhibitor
SC	subcutaneous
SHFS	Seattle Heart Failure Score
SL	sublingual
SNRI	serotonin–norepinephrine re-uptake inhibitor
SSRI	selective serotonin re-uptake inhibitor
TD	transdermal
tds	three times a day
VAD	ventricular assist device
VF	ventricular fibrillation
VO ₂ max	maximal oxygen consumption
VT	ventricular tachycardia
WHO	World Health Organization
WPA	health/welfare power of attorney

Contents

Detailed contents *vii*
Contributors *xi*
Acknowledgement *xii*
Symbols and abbreviations *xiii*

1	The challenge of patients with heart failure (HF): barriers to accessing supportive and palliative care	1
2	The physiology of patients with HF: the origin of symptoms and rationale for treatment	9
3	Prognostication and disease trajectory	31
4	Communication in HF	41
5	Diagnosing end-stage heart disease	59
6	Integrating supportive and palliative care	73
7	Optimizing management in end-stage HF	87
8	Advance care planning (ACP)	103
9	Management of pain	113
10	Symptoms other than pain	141
11	Psychological and psychosocial aspects of HF	149
12	CPR and device therapy at the end of life	159
13	Care of the dying	169
14	Spiritual and religious care	179
15	Supporting carers	195

Index 211

Detailed contents

Contributors *xi*

Acknowledgement *xii*

Symbols and abbreviations *xiii*

1 The challenge of patients with heart failure (HF): barriers to accessing supportive and palliative care

Karen Hogg **1**

Introduction 2

Barriers to accessing supportive and palliative care 4

2 The physiology of patients with HF: the origin of symptoms and rationale for treatment

Shona Jenkins and Karen Hogg **9**

Definition and classification of HF 10

Aetiology of HF 12

Pathophysiology of HF 14

Symptoms of HF 18

Treatment of HF 20

3 Prognostication and disease trajectory

Karen Hogg **31**

Introduction 32

Scoring systems and prognostication 34

The relevance of scoring systems in the assessment of
palliative care needs 36

Escaping 'prognostic paralysis' 38

4 Communication in HF

Suzanne Kite **41**

Introduction 42

What needs to be communicated? 44

Principles of effective communication 46

Barriers to communication 50

Facilitators of effective communication in HF 52

Communication in specific situations 54

The role of family and carers 58

5 Diagnosing end-stage heart disease

Miriam Johnson

59

Introduction 60

The GSF 62

Barriers to diagnosing end-stage disease 64

Importance of diagnosing end-stage disease 66

Diagnosing dying—the terminal phase 68

Listening to the patient and family/carers 70

6 Integrating supportive and palliative care

Miriam Johnson

73

Introduction 74

The need for supportive and palliative care 76

Triggers for supportive and palliative care 78

Key people to integrate supportive and palliative care 82

Suggested transition points to consider reassessment of
supportive and palliative care needs 84

What's needed? 86

7 Optimizing management in end-stage HF

Karen Hogg

87

Introduction 88

Diuretics 90

Disease-modifying medications 92

Renal failure 94

Other factors 96

Device therapy and arrhythmia management 98

Optimizing HF management appropriately for
end of life care 100

8 Advance care planning (ACP)

Suzanne Kite and Karen Hogg

103

Introduction 104

Power of attorney (POA) 108

ACP and the medical management plan 110

9 Management of pain

Miriam Johnson

113

Introduction 114

Causes of pain 116

Types of pain 118

Assessment of pain 120

What hinders pain management? 122

Principles of management: the WHO analgesic ladder 124

Managing opioid side-effects 130

Pain syndromes 132

Topical methods of analgesia 134

Episodic, movement related, or incident pain 136

Chronic pain clinic referral and anaesthetic procedures 138

Referral to the palliative care team 140

10 Symptoms other than pain

Miriam Johnson

141

Introduction 142

Breathlessness 144

Other symptoms 146

11 Psychological and psychosocial aspects of HF

Miriam Johnson

149

Introduction 150

Coping 152

Depression 154

Anxiety 156

12 CPR and device therapy at the end of life

Karen Hogg and Miriam Johnson

159

General issues 160

CPR 162

Withdrawal of ICD support 164

Points to consider 168

13 Care of the dying*Miriam Johnson***169**

General issues 170

General approach to care of the dying 172

SC administration of furosemide 174

Care after death 176

14 Spiritual and religious care*Edwina Brown, E Joanna Chambers, and**Celia Eggeling, adapted by Miriam Johnson***179**

Introduction 180

Spiritual care 182

Assessing spiritual and religious needs 184

Possible spiritual issues for the patient with
end-stage cardiac disease 186Religious practices of different faiths in relation to
end of life care 188

15 Supporting carers*James Beattie and Max Watson***195**

The role of carers 196

Impact of chronic HF on patients 198

Impact of chronic HF on carers 200

Elements of carer burden and risk 202

Supporting informal carers 204

Disease-related variability 206

Bereavement care 208

Support providers 210

Index 211

The challenge of patients with heart failure (HF): barriers to accessing supportive and palliative care

Introduction 2

Barriers to accessing supportive and palliative care 4

Introduction

HF is a major public health problem, which is escalating due to the aging population, improved survival rates from acute cardiac syndromes, and the impact of secondary prevention. Therapy for HF has increased survival and improved symptoms.

Potential therapeutic strategies for HF include:¹⁻³

- Conventional drug therapy.
- Complex device therapy:
 - implantable cardioverter defibrillator (ICD)
 - cardiac resynchronization therapy (CRT).
- Ventricular assist devices.
- Cardiac transplantation.

However, symptom burden and mortality remain high, and for many quality of life is poor on a scale similar to or worse than for many common cancers. Despite this, patients with HF still lack routine access to palliative care services.³⁻⁶ Patients in developed countries tend to be elderly (average age 76) with concomitant comorbidities and psychosocial problems associated with age and chronic disease.^{3,7} Failure to address the supportive and palliative care needs of this patient group risks the following:

- Persistent symptom burden.
- Prolonged caregiver burden.
- Loss of opportunity to be involved in planning for end of life care.
- Risk of inappropriate and most often prolonged hospital admissions.
- Risk of inappropriate and unwanted hospital death.

These unmet needs are well known but barriers exist that until recently have deterred the provision of palliative care for people with HF. However, although challenging, providing this type of care and service has been deemed an international public health priority.^{8,9}